NCT04267939: ATR Inhibitor BAY 1895344 Plus Niraparib Phase 1b Study in Advanced Solid Tumors and Ovarian Cancer

NCT04267939
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER++, PR+
Other Mutations: DNA damage repair mutations
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Ph+ase 1
Drug Category: Serine-Threonine Kinase Inhibitor, Misc Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older ¬† (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Patients must have tumor(s) that express DNA damage repair mutations; Breast cancer patients are only eligble for the dose escalation phase (Part A)
Exclusions: Patients with prior treatment of an ATR Inhibitor
https://ClinicalTrials.gov/show/NCT04267939

Comments are closed.

Up ↑